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Abstract
Background: Convenient once-a-week dosing has made mefloquine a popular choice as malaria
prophylaxis for travel to countries with chloroquine-resistant malaria. However, the increased use
of mefloquine over the past decade has resulted in reports of rare, but severe, neuropsychiatric
adverse reactions, such as anxiety, depression, hallucinations and psychosis. A direct causality
between mefloquine and severe reactions among travelers has been partly confounded by factors
associated with foreign travel and, in the case of therapeutic doses of mefloquine, the central
nervous system manifestations of Plasmodium infection itself. The present case provides a unique
natural history of mefloquine-induced neuropsychiatric toxicity and revisits its dose-dependent
nature.
Case presentation: This report describes an acute exacerbation of neuropsychiatric symptoms
after an unwarranted therapeutic dose (1250 mg) of mefloquine in a 37-year-old male previously
on a once-a-week prophylactic regimen. Neuropsychiatric symptoms began as dizziness and
insomnia of several days duration, which was followed by one week of escalating anxiety and subtle
alterations in behaviour. The patient's anxiety culminated into a panic episode with profound
sympathetic activation. One week later, he was hospitalized after developing frank psychosis with
psychomotor agitation and paranoid delusions. His psychosis remitted with low-dose quetiapine.
Conclusion: This report suggests that an overt mefloquine-induced psychosis can be preceded by
a prodromal phase of moderate symptoms such as dizziness, insomnia, and generalized anxiety. It
is important that physicians advise patients taking mefloquine prophylaxis and their relatives to
recognize such symptoms, especially when they are accompanied by abrupt, but subtle, changes in
behaviour. Patients with a history of psychiatric illness, however minor, may be at increased risk
for a mefloquine-induced neuropsychiatric toxicity. Physicians must explicitly caution patients not
to self-medicate with a therapeutic course of mefloquine when a malaria diagnosis has not been
confirmed.
Background
Mefloquine, a 4-quinoline methanol structurally related
to quinine, has a long elimination half-life of 14 to 41
days [1], which allows for once-a-week dosing and makes
it a popular choice as malaria prophylaxis for travelers to
malaria endemic areas. Along with atovaquone/proguanil
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and doxycycline, mefloquine is currently recommended
as malaria prophylaxis for travel in areas with chloro-
quine-resistant Plasmodium falciparum by health authori-
ties in the United States, the United Kingdom, and
Canada [2,3]. The current recommended prophylactic
dose is 250 mg once a week for adults. Since mefloquine
was introduced in 1985, the most commonly reported
adverse events have been gastrointestinal and neuropsy-
chiatric events [4,5]. It is the latter that has been the most
concerning to the public. Common neuropsychiatric
adverse events include dizziness, insomnia, and strange or
vivid dreams. The increased use of mefloquine over the
past two decades, due to increased international travel to
malaria endemic areas, has resulted in reports of less com-
mon, but more severe, neuropsychiatric reactions such as
anxiety, depression, hallucinations and psychosis. Due to
the relative rarity of events, the causal relationship
between mefloquine and these severe reactions among
travelers is tenuous, often confounded by factors associ-
ated with foreign travel and, in the case of therapeutic
doses of mefloquine, the central nervous system (CNS)
manifestations of Plasmodium infection itself.
This report describes an acute exacerbation of neuropsy-
chiatric symptoms after an unwarranted therapeutic dose
(1250 mg) of mefloquine in a 37-year-old male previ-
ously on a once-a-week prophylactic regimen. The case
demonstrates the time course of mefloquine-induced
neuropsychiatric toxicity, revisits the dose dependent
nature of such adverse events, and reviews the current lit-
erature.
Case presentation
Mr. A, a 37-year-old Nigerian male who has lived in the
United States for ten years, traveled to Nigeria for one
week with his wife to visit family. He had never taken
mefloquine prophylaxis before this trip, but his child-
hood was remarkable for multiple episodes of malaria
treated with various anti-malarial regimens. His previous
psychiatric history was significant for a single panic attack
experienced in his early twenties. He had no medical diag-
noses prior to these events. He used no alcohol or other
substances and had no known drug allergies.
Mr. A began his malaria prophylaxis regimen of once-a-
week, 250 mg mefloquine two weeks prior to traveling to
Nigeria. He and his wife spent a week in urban regions of
his native country without incident. He discontinued his
malaria prophylaxis upon returning to the United States.
Two weeks later, Mr. A began experiencing fatigue and a
mild headache and presented to a university-affiliated
travel clinic. He denied fever, chills, night sweats, or nau-
sea. Chemistries and cell blood count were within normal
limits, and a blood smear showed no evidence of parasi-
taemia.
Two weeks after his visit to the travel clinic, Mr. A, still
concerned that he might have malaria, took a one-time
therapeutic dose of 1250 mg mefloquine. The next day, he
began experiencing vertigo and insomnia, both which
lasted for several days. While at work that same week, he
experienced chest pain radiating down his left arm with
concomitant diaphoresis and tachycardia in what the
patient described as "an ACS picture," referring to acute
coronary syndrome. He felt intense anxiety at this time.
Mr. A's blood pressure taken in his office was 210/110. He
then went to the emergency department of an outside hos-
pital and was admitted for a hypertensive emergency. Car-
diac work-up for ACS, including an exercise stress test, was
negative and head computerized tomography showed no
abnormalities other than a left maxillary mucosal inclu-
sion cyst suggestive of sinusitis. Mr. A was diagnosed with
hypertension and, incidentally, with Type II diabetes mel-
litus. He was held overnight for observation and dis-
charged the following morning on metoprolol 100 mg
qd, lisinopril 10 mg qd, rosiglitazone 1 mg bid, and met-
formin 500 mg bid, and zolpidem 10 mg qhs. The follow-
ing Monday morning, he returned to work at his office,
but left midday because he was experiencing anxiety and
nervousness. He did not return to work the rest of the
week and tried to relieve his anxiety with exercise and out-
door activities. During this week, he began having unu-
sual conversations about spirituality and religion with his
wife. His wife reported that he had difficulty following
conversations and was remarkably suspicious of her as
well, with numerous inquiries into her activities and
friends.
Nine days after the previous hospital discharge, Mr. A
became abruptly anxious and agitated with delusions that
his wife was having an extramarital affair and began "talk-
ing out of his head." His wife, fearful of his increasing agi-
tation and paranoia, finally coaxed Mr. A into going to the
emergency department at a university-affiliated hospital.
He became severely agitated and paranoid in the emer-
gency department, becoming highly suspicious of the
one-to-one sitter ordered for his safety after he had
reported suicidal ideation. He attempted to escape from
the hospital. Eventually, Mr. A had to be restrained to his
bed due to profound psychomotor agitation. His vital
signs were remarkable for a blood pressure of 157/97, and
physical examination was significant only for altered
mental status. Serum electrolytes, renal function, and cell
blood count were within normal limits. Blood glucose
was mildly elevated at 146 mg/dL. Urine drug screen was
negative. Urinalysis was positive for bacteriuria, and a
course of levofloxacin was initiated. Mr. A was admitted to
the general medicine service, where overnight he had
another acute episode of agitation, becoming increasingly
argumentative with the staff. Intramuscular haloperidol
was administered to treat his acute psychotic agitation.Malaria Journal 2006, 5:74 http://www.malariajournal.com/content/5/1/74
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Mr. A was transferred to the medical psychiatry inpatient
unit with the DSM-IV-TR diagnosis of Psychotic Disorder,
Not Otherwise Specified. His vital signs remained stable.
Rapid plasma reagin test, cobalamin and folate levels,
liver transaminase levels, and thyroid stimulating hor-
mone levels were within normal limits. Mr. A complained
of intense anxiety with no identifiable precipitant on the
first day of his hospital course. He demonstrated paranoid
behaviour and was highly suspicious of the staff, fre-
quently checking identification badges and quizzing the
staff in order to verify their background and knowledge.
Although generally cooperative, he questioned the utility
of all procedures indicated in his treatment. He was
started on quetiapine 25 mg qhs, alprazolam 0.5 mg bid
and zolpidem 5 mg qhs. The latter two medicines were
both started during his previous hospitalization for hyper-
tensive crisis. He was also maintained on his previous
anti-hypertensive (metoprolol 100 mg qd and lisinopril
10 mg qd) and diabetic (rosiglitazone 1 mg bid, and met-
formin 500 mg bid) regimens. An electroencephalogram
was performed, and the results were negative and incon-
sistent with delirium or encephalopathy. His vital signs
were stable and within normal limits.
The next day, he reported that he refused quetiapine the
previous night (confirmed with the nursing staff), citing
that his paranoia and delusions had resolved. His claims
were incongruent with his behaviour, as he was even more
inquisitive than previously, again challenging the staff on
their medical knowledge and questioning the rationale
behind his medical treatment. He requested that he see
his medications delivered in their original packaging
before taking them. He eventually took his psychotropic
medications but refused diabetic management on
grounds that he wanted a subspecialist to manage his dia-
betes. Work-up for pheochromocytoma, porphyria, and
heavy metal toxicity was negative. Over the next couple
days, Mr. A's paranoia remitted in response to low dose
quetiapine, and he became more pleasant, agreeable, and
less suspicious. He eventually agreed to the nursing staff
dispensing all his medications and to routine manage-
ment of his diabetes. On day six of admission, Mr. A
stated that he felt more trusting and was completely agree-
able to the treatment and discharge plan, although he still
found it difficult to follow conversations. After confirm-
ing follow-up appointments with Mr. A and his wife and
obtaining assurances that he would not return to work
until after clearance by an outpatient psychiatrist, Mr. A
was discharged on quetiapine 100 mg qhs, metoprolol
100 mg qd, lisinopril 10 mg qd, rosiglitazone 1 mg bid,
and metformin 500 mg bid.
Conclusion
Mr. A's initial presenting symptoms in the travel clinic
were fatigue and a mild headache, both non-specific
symptoms that may or may not be attributable to meflo-
quine. One can assume that Mr. A tolerated the prophy-
lactic mefloquine regimen relatively well as evidenced by
the absence of serious neuropsychiatric symptoms during
and immediately after his three-week course. However,
these lingering non-specific symptoms prompted him to
take a therapeutic dose of mefloquine despite a negative
blood smear. His neuropsychiatric symptoms appeared
the next day, concomitant with the presumed peak of
mefloquine, which reaches maximum concentration in
the blood within 24 hours of an oral dose [1].
Mr. A's risk factors for mefloquine-induced psychosis
include previous use of anti-malarials for childhood
malaria and a single panic attack that occurred ten years
prior to this psychotic episode. Drug interactions between
mefloquine and anti-hypertensive or anti-diabetic medi-
cations may have contributed to the psychosis, but this is
unlikely given that Mr. A experienced sleep disturbances,
vertigo, anxiety and a panic attack prior to being diag-
nosed with diabetes and hypertension. Current literature
lacks evidence of such interactions aside from one study
which demonstrated that mefloquine inhibited the
metabolism of metoprolol [6]. Similarly, the contribution
of incidental bacteriuria to Mr. A's altered mental status is
plausible but unlikely, given that he had neither pre-exist-
ing cognitive impairment nor clinical findings that would
suggest a complicated urinary tract infection. Levofloxacin
was used to treat his bacteriuria after the initial onset of
neuropsychiatric symptoms. Interestingly, levofloxacin is
a fluoroquinolone antibiotic structurally related to meflo-
quine but has a low overall rate of serious CNS adverse
events, with such events occurring in only 4 per 100 000
treated patients [7]. Whether levofloxacin can contribute
to pre-existing neuropsychiatric symptoms in an additive
manner has yet to be formally investigated. Mr. A's psy-
chotropic medications should not have contributed sig-
nificantly to his psychotic presentation. Both alprazolam
and zolpidem are short-acting drugs that were well toler-
ated at low doses for one week prior to the acute psychotic
episode. In addition, alprazolam, as are other benzodi-
azepines, has an insignificant risk of inducing psychosis;
in fact, this class of drugs has been used in the treatment
of acute psychosis [8-10]. It is important to note that
zolpidem has been reported to induce psychosis at much
higher doses, but this phenomenon has been limited to
women [11].
A review of neuropsychiatric adverse events in an esti-
mated 1.2 million mefloquine prophylaxis users from
continental Europe demonstrated only 278 adverse events
(0.023%), with the most commonly reported being dizzi-
ness, neuropathies, headaches, and psychiatric disorders
of affect [12]. The study was limited by its reliance on self-
reporting of adverse events and the use of a crude, overes-Malaria Journal 2006, 5:74 http://www.malariajournal.com/content/5/1/74
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timated denominator derived from drug sales rather than
actual compliance rates. More recent studies have consist-
ently demonstrated that neuropsychiatric adverse events
associated with prophylaxis are usually limited to dizzi-
ness, bizarre or vivid dreams, and insomnia, but with inci-
dence rates of 10–40% [4,5,13]. Anxiety is less common,
with one trial (n = 483) reporting an incidence of 4% in
non-immune travelers receiving mefloquine prophylaxis
[4]. Mefloquine-induced panic attacks and psychosis
appear to be even rarer events; an observational study of
16,491 subjects on mefloquine prophylaxis described
only 9 and 3 events, respectively, during the course of
mefloquine use [14].
Neuropsychiatric adverse events after therapeutic doses of
mefloquine have been difficult to study mainly because
malaria itself often causes CNS symptoms, and current
practices in endemic regions require mefloquine/artesu-
nate combination therapy due to increasing mefloquine
resistance [15]. Nevertheless, in a limited study of 22
healthy volunteers, almost all participants experienced
vertigo, nausea, or headache after a therapeutic dose of
mefloquine. Less common events included anxiety,
depression, confusion and hallucinations [16]. An earlier
risk analysis of malaria cases in Germany suggested that
therapeutic mefloquine increased the risk of neuropsychi-
atric adverse events by 60-fold over prophylactic doses
[17]. In the treatment of uncomplicated falciparum
malaria with mefloquine regimens, randomized, control-
led trials in Thailand have consistently shown dose-
related increases in both moderate and severe neuropsy-
chiatric adverse events [18-21]. Pronounced CNS toxicity
was seen in two cases of inadvertent mefloquine overdose
secondary to dispensing errors [22]. One patient devel-
oped confusion, agitation, ataxia, dizziness, speech diffi-
culties, and high-frequency hearing loss after taking 15
250 mg of mefloquine over two months. The other
patient complained of persistent weakness, depression,
disorientation, and paresthesia after taking 16 250 mg of
mefloquine within a six month period. In both cases,
mefloquine (Lariam) was mistakenly substituted for ter-
binafine (Lamisil). These data suggest that the incidence
and severity of neuropsychiatric events associated with
mefloquine use is dose-dependent. Interestingly, serious
adverse events do not seem to correlate with mefloquine
levels in the blood [23], implying that the risk of develop-
ing neuropsychiatric symptoms may be related to an indi-
vidual's threshold for mefloquine rather than absolute
mefloquine blood levels. The case presented here sup-
ports a dose-dependent effect of mefloquine neurotoxic-
ity, as Mr. A developed profound anxiety and subsequent
paranoid psychosis only after his dose was escalated from
250 mg to a one-time dose of 1250 mg.
To date, the effects of mefloquine on the CNS remain
unclear, given the limited literature on this topic. On a
biochemical level, there is evidence that mefloquine may
disrupt calcium homeostasis and induce a stress response
in rat neurons in vitro [24]. Also, mefloquine has been
shown to inhibit electrical coupling between interneurons
in slices of rat neocortex via blockade of gap junctional
channels [25]. At the clinical level, Croft and Herxheimer
critically reviewed 516 case reports and proposed that
mefloquine exerts its CNS effects via primary hepatotoxic-
ity and symptomatic thyroid dysfunction [26]. In the
present report, work up for hepatic and thyroid dysfunc-
tion was negative.
This case reveals a unique and insidious natural history of
mefloquine neurotoxicity. Prior to developing overt psy-
chosis, Mr. A had initially experienced vertigo and insom-
nia for several days followed by a full week of escalating
anxiety and subtle alterations in behaviour. His anxiety
culminated into a panic episode with profound sympa-
thetic activation within a week of taking therapeutic
mefloquine. This suggests that an overt mefloquine-
induced psychosis can be preceded by a prodromal phase
of moderate symptoms such as dizziness, insomnia, and
generalized anxiety. Taylor and White reviewed several
studies assessing the effect of mefloquine on psychomotor
performance and fine motor skills and concluded that
mefloquine did not significantly interfere with higher
mental function despite causing adverse effects such as
sleep disturbances and changes in affect [20]. The fact that
mefloquine toxicity does not usually hinder daily func-
tion may mask its potential severity. It is important that
physicians advise patients taking mefloquine and their
relatives to recognize specific symptoms, especially when
they are accompanied by abrupt but subtle changes in
behaviour.
Although psychosis is usually self-limited after meflo-
quine is discontinued, its adverse effects on the CNS may
continue for several weeks due to a long elimination half-
life. Therapy with atypical antipsychotics, such as risperi-
done, has shown to be effective in several cases, with psy-
chosis remitting within a few days [27-29]. Mr. A
responded within two days to low-dose quetiapine with
complete resolution of his psychomotor agitation and
paranoid delusions. Therefore, recognition of specific
neuropsychiatric symptoms and behavioural changes in a
patient taking mefloquine may prompt physicians to
more carefully assess the patient and intervene if necessary
before severe psychosis develops.
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